About this Journal

Systematic Reviews in Pharmacy (Sys Rev Pharm.), (SRP) (Print ISSN: 0975-8453, E-ISSN: 0976-2779) is a monthly Peer-review open access Journal, serves the need of different scientists and others involved in Pharmaceutical research and development. Each issue covers review articles on Drug discovery topics, and also publishes full length reviews related to different subjects in pharmacy and that are of broad readership interest to users in industry, academia, and government. The first issue was published online on December 2009.

All contribution to Sys. Rev Pharm are reviewed by peer review process and copyediting process with the understanding that they have not been published previously and are not under consideration for publication elsewhere. Author/s is/are responsible for all statements made in their work and obtaining necessary permission to republish any previously published illustrations and/or other relevant materials. The journal’s full text is available online at https://www.sysrevpharm.org . The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.

The journal has transferred from Synthesis Hub Advance Scientific Research to the present handling editors and the journal is running independently.

Scope of the journal

The journal covers and publishes all articles related to Pharmacy subjects including some of the allied subjects. Articles with timely interest and newer research concepts will be given more preference.

This journal also publishes manuscripts related to pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, clinical, Biomedical Research, and Biomedical sciences. Other topics include all aspectsplant and animal nutrition, medical law, law and education, and the application of new analytical and study methods (including new analytical and bio-analytical techniques).

Viagra est la forme commerciale du médicament inhibiteur de la phosphodiestérase de type 5 (PDE5), le sildénafil, et est approuvé pour le traitement de la dysfonction érectile (DE) chez les hommes âgés de 18 ans et plus (Medical News Today, 2023). La stimulation sexuelle est toujours nécessaire pour que le acheter Viagra sans ordonnance (sildénafil) agisse (SingleCare, 2022). La "petite pilule bleue" est considérée comme le médicament contre la dysfonction érectile qui a donné le coup d'envoi de la deuxième révolution sexuelle, lorsqu'elle a été mise sur le marché en 1998 (BBC, 2023). Viagra est la forme commerciale du médicament inhibiteur de la phosphodiestérase de type 5 (PDE5), le sildénafil, et est approuvé pour le traitement de la dysfonction érectile (DE) chez les hommes âgés de 18 ans et plus (Medical News Today, 2023). La stimulation sexuelle est toujours nécessaire pour que le acheter Viagra sans ordonnance (sildénafil) agisse (SingleCare, 2022). La "petite pilule bleue" est considérée comme le médicament contre la dysfonction érectile qui a donné le coup d'envoi de la deuxième révolution sexuelle, lorsqu'elle a été mise sur le marché en 1998 (BBC, 2023).